PubMed Health⌕ Search

Biomedical subjects

D Leis

Publications and source records attributed to D Leis.

12 recordsLinked to original sources
PubMed1983

Hormonal profile and glucose tolerance in late pregnancy and postpartum.

Oral glucose tolerance, plasma insulin and basal levels of glucagon, hGH, hPRL, hPL, TSH, T4, T3, thyroxine-binding globulin (TBG), cortisol, corticosteroid-binding globulin (CBG) and estriol were measured in 23 normal pregnant women in late gestation (31 +/- 0.4 weeks of pregnancy). Twelve of these subjects could be re-examined 14 +/- 2 weeks postpartum. Blood glucose was lower basal and after glucose load (100 g) in the pregnant group. Fasting plasma insulin and glucose-induced insulin release were higher in pregnancy. The insulinogenic index and the beta cell response were significantly greater antepartum, while peripheral insulin activity was unchanged. The insulin:glucagon ratio as well as TSH and hGH showed no significant differences between ante- and postpartum values. However, T4, T3, TBG, cortisol, CBG, estriol, hPRL and hPL were significantly higher during gestation than after delivery. T4:TBG and T3:TBG ratios were much lower antepartum, while the cortisol:CBG ratio was comparable ante- and postpartum. To our knowledge this is the first report in which such an extensive hormonal and metabolic analysis was performed in the same women ante- and postpartum. It could be shown that glucose tolerance is not worsened during pregnancy in healthy subjects. The higher gestational insulin values are discussed with respect to the various significant hormonal changes.

Blood Glucose↗
PubMed1981

The effect of oral estrogen therapy on serum FSH and LH levels in young women with hyper-gonadotrophic ovarian failure.

Fourteen women, 18--46 years old (median age: 28 years) with hypergonadotrophic ovarian failure were each treated daily for 21 days with 10 micrograms, 20 micrograms, 40 micrograms, and 60 micrograms ethinyl estradiol, 2,000 micrograms estriol, and 1,250 micrograms conjugated estrogens in six or more consecutive treatment cycles in a randomly assigned sequences. Before treatment and at the beginning of the 3rd week of each of the mentioned estrogen regimens, basal serum FSH and LH levels were measured. During the last 5 days of each treatment cycle, 10 mg of oral norethisterone acetate were given in addition to the estrogen, and after a treatment-free interval of 7 days the next estrogen regimen was begun according to the random list. FSH values were inversely related to the various dosages of ethinyl estradiol; the upper normal range with the exception of the periovulatory phase was reached with 40--60 micrograms ethinyl estradiol. FSH levels during treatment with 1250 micrograms of conjugated estrogens were similar to those found during treatment with 20 micrograms ethinyl estradiol. When 2,000 micrograms of estriol were given daily, FSH levels rose of pretreatment values. LH behaved similarly except that during treatment with 2,000 micrograms of estriol and 10 micrograms of ethinyl estradiol values above pretreatment levels were found.

Administration, Oral↗
PubMed1981

[The early diagnosis of pregnancy by the enzyme immunoassay of beta-1-glycoprotein (sp1) (author's transl)].

The enzyme immunologic determination of SP1 in the serum is suitable for the early diagnosis of pregnancy from 14 days after ovulation onwards. In the control group of 64 non-pregnant and of healthy men no SP1 was detected in the serum. At least six weeks after the cessation of trophoblast activity SP1 can still be detected in the serum. The enzyme immunoassay technique of SP1 in the serum has a high sensitivity of 1 ng/SP1/ml serum and a short measuring time of 2 1/2-4 hours. This test is therefore excellent for the early diagnosis of pregnancy.

Adolescent↗
PubMed1980

Effects of low-dose gestagen (lynestrenol 0.5 mg) and combination-type oral contraception (lynestrenol 1 mg and ethinyloestradiol 0.05 mg) on blood glucose and serum insulin levels after a glucose load.

Forty 3-h oral glucose tolerance tests (OGTTs) were performed in 10 apparently healthy female volunteers aged 21--34 years, each serving four times as her own control. Each subject was taking either a low-dose gestagen contraceptive (lynestrenol 0.5 mg) or a combination-type pill (lynestrenol 1 mg + ethinyloestradiol 0.05 mg) alternatingly in four consecutive treatment cycles. Blood glucose and serum insulin did not differ significantly with either contraceptive (paired t-test).

Adult↗
PubMed1980

The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. A study of 17 patients under treatment for endometrial cancer.

Seventeen women aged 55 to 76 years who had been treated for endometrial cancer by surgery or radiotherapy or a combination of both were given 300 mg of medroxyprogesterone acetate (MPA) daily by mouth. Before treatment and again during the 3rd week of treatment an oral glucose tolerance test (with measurement of serum insulin levels) and an ACTH-stimulation test were done. All blood glucose levels tended to be higher with MOA therapy and serum insulin levels were significantly increased 3 h after a glucose load. The rise of serum cortisol 30 min after ACTH-stimulation was significantly less with MPA therapy. Oral MPA thus appeared to have a glucocorticoid-like action.

Adrenal Glands↗
PubMed1979

[Comparison of the sebaceous secretions of the skin of the forehead under the treatment with three oral contraceptives. Diane, Neogynon and Lyndiol (author's transl)].

Ten women who took oral contraceptives for six months or longer were investigated. The women took in a randomized sequence cyproteronazetate 2 mg. ethinyloestradiol 50 mcg. (Diane), D-Norgestrel 0.25 mg., ethinyloestradiol 50 mcg. (Neogynon), and Lynestrenol 2.5 mg. with ethinyloestradiol 50 mcg. (Lyndiol). During each treatment cycle at four defined pounts the sebaceous secretions from the skin of the forehead was measured. Since each patient received one cycle of each of the oral contraceptives each patient served as her own control. With Diane and Neogynon the sebaceous secretions were the same. With ingestion of Lyndiol there was a significantly higher sebaceous secretion than with the other two oral contraceptives (p less than 0.05, t-test for paired observations).

Adult↗
PubMed1978

[Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leucine amino peptidase (LAP), alkaline phosphatase (AP), and bilirubin in 30 hysterectomized and ovarectomized women (author's transl)].

UNLABELLED: 30 hysterectomized and ovarectomized women were treated with three different estrogens: EE2 orally, E3 orally, and E3-suc intramuscularly. Each patient received one substance over 5 days doubling the dose every consecutive day, and switching to another estrogen after a treatment free interval of 2 days, rising the dosage of the second preparation twofold every consecutive day over another 5 days. Thus, each patient served as her own control with respect to 2 of the 3 tested estrogens. Six groups were required to test all sequences possible. The patients were allocated by random. GOT, GPT, LAP, AP and bilirubin were estimated daily over 2 weeks. The starting dose of EE2 was 0.25 mg, of E3 2 mg, and of E3-suc 2.5 mg. RESULTS: There were marked elevations of all serum enzymes during the week of EE2 treatment. If EE2 was given in the first week, and either E3 or E3-suc in the second one there was a prompt fall of all enzyme levels in spite of the approximately tenfold higher dose of the latter two estrogens. There were only minor elevations of the enzymes after oral E3 and parenteral E3-suc in some subjects and no differences of response between these two estrogens. Bilirubin reacted with an overall rise in the majority of patients irrespective of the type of estrogen.

Adult↗
PubMed1978

[Spontaneous hyperstimulation of the ovaries with luteal cysts and ascites during a twin pregnancy-extreme case of the syndrome of painfull early pregnancy (author's transl)].

Laparotomy was performed in a para II gravida II of 28 years in an early twin pregnancy. The left ovary was enlarged to 18 X 8 cm, the right ovary to 1i X 8 cm by luteal cysts. The abdominal cavity contained an ample amount of peritoneal fluid. The history is understood as spontaneous ovarian hyperstimulation, and as an extreme case of the relatively common syndrome of painfull early pregnancy, occasionally leading to unnecessary surgical intervention.

Abdomen, Acute↗
PubMed1977

Comparison of ethinylestradiol and mestranol in sequential-type oral contraceptives in their effects on blood glucose and serum insulin in oral glucose tolerance tests.

Forty 3-hour oral glucose tolerance tests (OGTTs) were performed in 10 assumedly healthy female volunteers 19 to 30 years old, each serving four times as her own control. Each subject was taking a sequential type oral contraceptive containing either 50 microgram of ethinylestradiol or 80 microgram of mestranol alternatingly in four consecutive treatment cycles. The OGTTs were performed on the 6th day of each cycle, during pure estrogen medication. Blood glucose and serum insulin values did not differ significantly under either estrogen as tested by the t-test for paired observations. Our results do not support the findings of others that mestranol has a more pronounced or even exclusively adverse effect on glucose tolerance as compared with ethinylestradiol.

Adult↗
PubMed1968

[Shock].

Explore the source record for details and available documents.

First Aid↗